AGP Executive Report
Last update: 8 hours agoDrug Access: China’s updated insurance lists add a record 51 innovative medicines, including the country’s first CAR-T therapy; expanded coverage takes effect Jan. 1, 2027. Obesity Care: A Chinese-led study in Nature backs a diagnosis that goes beyond BMI, incorporating measures such as waist size and signs of harm to health. China has also approved its first oral weight-loss drug. Gene-Editing Safety: Two researchers were dismissed after a six-year-old died in an experimental gene-editing trial, renewing scrutiny of clinical safeguards. Cancer Treatment: The FDA declined to approve China-developed lung cancer drug ivonescimab after a trial failed to show a significant survival benefit.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.